Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the launch of Rafael Trial Connect, a web portal available on the Company’s website that will serve as a resource to both patients and physicians in search of clinical trial information and resources.
The new portal was created with the purpose of helping cancer patients access clinical trial information in a more user-friendly manner, as well as acting as a resource to oncologists by providing up-to-date trial information. The sleek design is functional and easy to navigate, providing key eligibility criteria and exclusion details, as well as trial site locations in a format that aims to eliminate the confusion that can arise in a clinical trial search.
“We are incredibly pleased with the launch of Rafael Trial Connect,” said Sanjeev Luther, President and CEO of Rafael. “We believe that this portal will enable cancer patients to make the most informed decisions regarding their care. We know that a cancer diagnosis can be both heartbreaking and confusing, and we want to do what we can to ease the burden for patients, their families and physicians by providing access to all of our resources and information in one place.”
Rafael Trial Connect contains direct links to Rafael’s ongoing clinical trials in acute myeloid leukemia (AML), Burkitt’s lymphoma and metastatic pancreatic cancer. There are informational links available to both patients and physicians about the clinical trial process, and as more Rafael clinical trials open, they will be added to the portal.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Rafael Trial Connect is the first step in the company’s goal of revamping its digital presence in order to make information more easily accessible to patients and physicians worldwide, and ultimately, improving treatment options for those battling cancer.
Date: August 7, 2019
Source: Yahoo
